14-10-2026 17:23 via drugs.com

EASD: Daily Orforglipron Pill Shows Comparable Cardiovascular Safety to Insulin Glargine

WEDNESDAY, Oct. 14, 2026-- The daily orforglipron pill has comparable cardiovascular safety to insulin glargine daily injections while providing additional benefits for adults with type 2 diabetes at increased cardiovascular risk, according to a...
Read more »

Pharmaceutical Industry news



Prepregnancy HPV Vaccination Linked to Lower Risk for Adverse Pregnancy Outcomes
Surrogates Less Likely to Recommend Life-Sustaining Treatment for Patients With Dementia
AHA: Increased Potassium Intake With DASH Diet Does Not Lead to Hyperkalemia
AAO: Raytracing-Guided LASIK Enhancement Improves Visual Function After Cataract Surgery
Active Acupressure Offers Clinical Benefits for Rosacea
EASD: Petrelintide Achieves Weight Loss for Adults With Obesity
Guideline Developed for Treatment of Menopausal Vasomotor Symptoms
AAP Updates Recommendations on Management of UTI in Children Younger Than 5
American Academy of Pediatrics, Oct. 2-6
American Society for Radiation Oncology, Sept. 26-30
American College of Surgeons, Sept. 26-29
Misdiagnosis More Common for Women With Autoimmune Disease
Lifetime Risk for Heart Failure High and Increasing
Minibeam Radiotherapy Promising for Cutaneous, Soft Tissue Malignancies
Desktop versie